Sun Pharma gets USFDA nod for generic drug Mesalamine extended release capsules

PTI

New Delhi, May 12

Sun Pharmaceutical Industries on Thursday said it has received final approval from the US health regulator for Mesalamine extended release capsules, used to treat bowel disease, in the American market.

The company has received approval from the US Food and Drug Administration (USFDA) for the product, a generic version of Pentasa extended release capsules (500 mg), the Mumbai-based drug major said in a statement.

As per March 2022 IQVIA Health data, Pentasa had annualised sales of around USD 213 million in the US market.

#sun pharma
#usfda

Stay connected with us on social media platform for instant update click here to join our T witter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Health & Fitness News Click Here

Read original article here

Denial of responsibility! Rapidtelecast.com is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.